Skip to search formSkip to main contentSkip to account menu

Anti-interferon gamma Monoclonal Antibody NI-0501

Known as: Anti-IFN gamma Monoclonal Antibody NI-0501, Anti-IFNg mAb NI-0501, NI-0501 
A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
IFNɣ Block, Treosulfan Conditioning and αβ T Cell Deplete PBSCT for XIAP-Deficient HLH
2016
2016
Anti-interferon gamma monoclonal antibody NI-0501: A new option to render allogeneic HSCT for HLH safer and more effective?
2016
2016
First EU PRIME designations
The names of the first four drugs to receive PRIME (PRIority MEDicines) status were released in June by the European Medicines… 
2016
2016
Stemcentrx bags $5.8 billion, even as Notch agent underwhelms
Highly Cited
2015
Highly Cited
2015
A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2…
Introduction Primary HLH (pHLH) is a rare immune regulatory disorder invariably lethal if untreated. It is driven by pathologic… 
2015
2015
Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis
Background A growing body of evidence, in animals and humans, suggest that IFNg plays a pathogenic role in primary HLH (pHLH) and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)